Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 3/20 | 0.42 |
| ▸ | SMAD3 | P84022 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | VDR | P11473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10727137 | 0.78 | MAPT (0.58) | MAPTALDH1A1LMNAKDM4EALOX12 | |
| SCHEMBL10727154 | 0.75 | MAPT (0.63) | MAPTALDH1A1LMNAKDM4EALOX12 | |
| SCHEMBL8291314 | 0.73 | MAPT (0.80) | MAPTALDH1A1LMNAKDM4EALOX12 | |
| SCHEMBL8289588 | 0.73 | MAPT (0.51) | MAPTALDH1A1LMNAKDM4EALOX12 | |
| SCHEMBL20105042 | 0.69 | CCNB2 (0.53) | MAPTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL27981621 | 0.66 | P4HB (0.67) | MAPTALDH1A1HTTP4HBSMAD3 | |
| SCHEMBL27981618 | 0.66 | P4HB (0.67) | MAPTALDH1A1HTTP4HBSMAD3 | |
| SCHEMBL2367267 | 0.65 | GSK3B (0.43) | MAPTALDH1A1LMNAKDM4EHSD17B10 | |
| SCHEMBL20105008 | 0.65 | CCNB2 (0.46) | MAPTALDH1A1LMNAKDM4EHSD17B10 | |
| SCHEMBL13708930 | 0.65 | MAPT (0.40) | MAPTALDH1A1LMNAKDM4EALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366394-A1 | Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase IV (DP IV) | IMTM GmbH (DE) | 2011-09-21 | — | — | EP | claimed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| WO-2011113895-A2 | CHARACTERIZATION AND VALIDATION OF INHIBITORS AND LIGANDS OF DIPEPTIDYL AMINOPEPTIDASE IV (DP IV) | IMTM GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2366394-A1 | Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase IV (DP IV) | IMTM GmbH (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2105441-A1 | Alanyl aminopeptidase and dipeptidylpeptidase IV dual inhibitors for the treatment of immunological, inflammatory, neuronal and other illnesses | IMTM GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005034940-A2 | DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | MAPT 1306/4885ALDH1A1 1472/4885HTT 1551/4885 |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | DNPEP, PREP, ANPEP | MAPT 1296/4885ALDH1A1 1151/4885HTT 2034/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | MAPT 1400/4885ALDH1A1 1025/4885HTT 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.